
Mosaic emerges with $47 million for sensing-enabled surgical robots
Mosaic co-founders Ileana Pirozzi (left) and Alison Mackanic (right). Photo: Mosaic Intelligence Labs, via The Next Web.Left to right: Dr. Ileana Pirozzi (Co-founder and CEO); Dr. Alison "Ali" Kight Mackanic (Co-founder and CTO).Mosaic Intelligence Labs has emerged from stealth with $47 million in seed funding to develop sensing-enabled surgical instruments and robotic systems. Its November 10 announcement names 8VC, Fundomo, Lingotto Innovation and Obvious Ventures among its backers. The Next Web reports that the total was raised across two seed rounds; it should not be read as one newly priced round with a disclosed valuation.
The San Francisco company is starting with endovascular procedures, in which doctors pass thin wires and catheters through blood vessels to reach a treatment site. A catheter is a flexible tube used to deliver instruments or treatment inside the body. Doctors currently combine live X-ray images, earlier scans and the feel of the instrument to work without a direct view of the vessel.
Mosaic is developing sensors at the point where instruments meet anatomy, computation that reconstructs the surrounding blood vessels, and a robotic interface for precise instrument control. The intended result is a continuously updated three-dimensional view of the anatomy and instrument position. This is hardware, sensing and control development, rather than an app placed on an existing surgical workflow.
Its longer-term approach links what instruments sense with their movement and the physician's actions. Recording those signals together could help systems learn how movements affect the surrounding anatomy. The current announcement describes a development programme, not an approved autonomous surgery product.
Founders Dr. Ileana Pirozzi, CEO, and Dr. Alison "Ali" Kight Mackanic, CTO, met during their doctoral studies at Stanford. Mosaic is recruiting in hardware engineering, sensing, perception, machine learning and clinical engineering in San Francisco.
The release does not disclose a regulatory clearance, a commercial launch date, clinical performance results, a valuation or an allocation of the $47 million between the two reported rounds. Its reference to surgical systems used to treat more than 20 million patients describes the team's prior experience, not patients treated with Mosaic's new platform.
DTT summary based on Mosaic Intelligence Labs / Business Wire's report. The full article is on the publisher's site.
Additional reporting
$47 million in seed funding; reported across two seed rounds.
8VC, Fundomo, Lingotto Innovation and Obvious Ventures.
Sensing-enabled instruments, 3D vascular reconstruction and robotic control.
Under development; no regulatory clearance or clinical performance data disclosed in the announcement.